Abstract
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Current Vascular Pharmacology
Title:Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Volume: 10 Issue: 6
Author(s): Marcello Arca, Giovanni Pigna and Carla Favoccia
Affiliation:
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Abstract: Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Export Options
About this article
Cite this article as:
Arca Marcello, Pigna Giovanni and Favoccia Carla, Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520864
DOI https://dx.doi.org/10.2174/157016112803520864 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) Dissolution Rate Enhancement of Repaglinide Using Dietary Fiber as a Promising Carrier
Current Drug Delivery Concurrent And Longitudinal Association Between Glycemic Control And Self Reported Medication Adherence Among Type 2 Diabetes Patients At A Tertiary Care Hospital In Malaysia
Current Diabetes Reviews Cell Adhesion Molecules and Cadmium
Current Chemical Biology Clinical Studies of Renal Nerve Ablation. Unanswered Questions for its Efficacy and Safety
Current Clinical Pharmacology Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy
Current Medicinal Chemistry Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?
Current Pharmaceutical Design Editorial (Thematic Issue: Nanotechnology as a Strategy to Improve Treatment of Diabetes)
Current Pharmaceutical Biotechnology Anti-diabetic Effect of Ginsenoside Rb3 in Alloxan-induced Diabetic Mice
Medicinal Chemistry Preconception Counselling: A Five- Year Experience in a Teratology Information Service
Letters in Drug Design & Discovery A Review of Statistical and Machine Learning Techniques for Microvascular Complications in Type 2 Diabetes
Current Diabetes Reviews Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Current Diabetes Reviews Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all
Current Pharmaceutical Design The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design Recent Patents and Advances in Hepatocyte-Like Cells Differentiation by Perinatal Stem Cells
Recent Patents on Regenerative Medicine